focus -WSS

focus

author：explore 2025-09-29 08:22:00 - browse：3159

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： The new shift in health care is toward less care

WSS

HPV cancer vaccine study demonstrates efficacy

Victims of gun violence feel impacts long after bullet wound

Results on Novartis prostate cancer therapy could expand its use

Senate panel clears PBM, hopsital reforms

Merck, Daiichi strike cancer drug pact worth up to $22 billion

STAT Executive Editor Rick Berke on STAT's 8th birthday

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Heart attack and stroke risk calculators need revising

Why a market frenzy over new weight loss drugs defies logic

Sports medicine is finally prioritizing gender equality

ADCs take center stage as promising cancer treatments

Bright Health sells Medicare Advantage business to Molina

Excited delirium, Elijah McClain, and emergency physicians

Apple is now the first public company to be valued at $3 trillion

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Sports medicine is finally prioritizing gender equality

STAT Readout Newsletter: Biotech news today

leisure time

Diversify hospital leadership teams to protect BIPOC patient health

FDA clears Verve to begin U.S. study of gene

STAT Readout: Friday, Oct. 20 biotech updates

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Senate panel clears PBM, hopsital reforms

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

entertainment

focus

Wikipedia

focus